EVALUTION OF THE PREDICTIVE ABILITY OF THE SCALES FOR RISK DEVELOPMENT STRATIFICATION OF ST, RISK-PCI AND PARIS STENT THROMBOSIS IN PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION


Cite item

Full Text

Abstract

The article studies the problems concerning the prevention of the stent thrombosis development after the invasive percutaneous coronary intervention in patients with acute coronary syndrome with ST segment elevation. The research was performed in the Samara Regional Clinical Cardiologic Dispensary within the period of 01.01.2012 to 31.12.2017. The aim was to predict the development of stent thrombosis. According to the current classification of the Academic Research Consortium patients with a definite stent thrombosis were examined. To identify the risk group, the ST, RISK-PCI and PARIS scales have been filled in for each patient. However, they have shown a low predictive ability to diagnose stent thrombosis in a high-risk group.

About the authors

I L Voronova

Samara State Medical University

Email: antikirina@mail.ru
Postgraduate student, Department of Cardiology and Cardiovascular Surgery of the IPE.

References

  1. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320
  2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology. EurHeart J. 2018;39(2):119-177. doi: 10.1093/eurheartj/ehx393
  3. Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angio-graphically documented early, late, and very late stent thrombosis. JACC CardiovascInterv. 2012;5(2):131-140. doi: 10.1016/j.jcin.2011.10.013
  4. Baber U, Mehran R, Giustino G, et al. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016;67(19):2224-2234. doi: 10.1016/j. jacc.2016.02.064
  5. Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306(16):1765-1774. doi: 10.1001/jama.2011.1529
  6. Claessen BE, Henriques JP, Jaffer FA, et al. Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv. 2014;7(10):1081-1092. doi: 10.1016/j. jcin.2014.05.016
  7. D’Ascenzo F, Bollati M, Clementi F, et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013;167(2):575-584. doi: 10.1016/j. ijcard.2012.01.080
  8. Dangas GD, Claessen BE, Mehran R, et al. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. JACC Cardiovasc Interv. 2012;5(11):1097-1105. doi: 10.1016/j. jcin.2012.07.012
  9. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. description of a new technic and a preliminary report of its application. Circulation. 1964;30:654-670
  10. FDA. Clinical Overview for Panel Packet DES Thrombosis Panel. December 7-8. 2006. http://www.fda.gov/ohrms/ dockets/ac/06/briefing/2006-4253b1_01.pdf
  11. Godschalk TC, Byrne RA, Adriaenssens T, et al. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Dueto Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry. JACC Cardiovasc Interv. 2017;10(24):2548-2556. doi: 10.1016/j.jcin .2017.09.019
  12. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126-2130
  13. Kelsey sF, Mullin SM, Detre KM, et al. Effect of investigator experience on percutaneous transluminal coronary angioplasty. Am J Cardiol. 1984;53(12):56-64
  14. Kereiakes DJ, Yeh RW, Massaro JM, et al. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv. 2015;8(12):1552-1562. doi: 10.1016/j. jcin.2015.05.026
  15. Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340-1348. doi: 10.1016/j.jacc.2012.06.043
  16. Kimura T, Morimoto T, Kozuma K, et al. Comparisons of baseline demographics, clinical presentation, and CLINICAL MEDICINE КЛИНИЧЕСКАЯ МЕДИЦИНА long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the registry of stent thrombosis for review and reevaluation. Circulation. 2010;122(1):52-61. doi: 10.1161/CIRCULATIONAHA.109.903955
  17. Lagerqvist B, Carlsson J, Frobert O, et al.; Swedish Coronary Angiography and Angioplasty Registry Study Group. Stent Thrombosis in Sweden A Report From the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv. 2009;2(5):401-408. doi: 10.1161/CIRCINTERVENTIONS.108.844985
  18. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382(9906):1714-1722. doi: 10.1016/S0140-6736(13)61720-1
  19. Mrdovic I, Savic L, Krljanac G, et al. Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score. Int J Cardiol. 2013;162(3):220-227. doi: 10.1016/j. ijcard.2011.05.071
  20. Mrdovic I, Savic L, Lasica R, et al. Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart Vessels. 2013;28(4):424-433. doi: 10.1007/s00380-012-0276-z
  21. Rinaldi MJ, Kirtane AJ, Piana RN, et al. Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events. Am Heart J. 2008;155:654-660
  22. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232-3245. doi: doi.org/10.1093/ eurheartj/ehw334
  23. Valenti R, Vergara R, Migliorini A, et al. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. J Am Coll Cardiol. 2013;61(5):545-550. doi: 10.1016/j.jacc.2012.10.036
  24. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53(16):1399-1409. doi: 10.1016/j. jacc.2008.12.055
  25. World Health Organization. Cardiovascular Diseases FactSheet. http://www.who.int/mediacentre/factsheets/ fs317/en/. Updated May 2017

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Voronova I.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).